Madrigal Pharmaceuticals price target raised to $443 from $427 at Citizens JMP
Citizens JMP raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $443 from $427 and keeps an Outperform rating on the shares.
Madrigal Pharmaceuticals price target raised to $475 from $400 at Oppenheimer
Oppenheimer raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $475 from $400 and keeps an Outperform rating on the shares ...
Hosted on MSN34m
Madrigal Pharmaceuticals Reports Strong 2024 Growth Fueled by Rezdiffra Launch
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced its financial results for 2024, marking a ...